Skip to main content
    T

    TG Therapeutics Inc (TGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $62.76
    -1.75 (-2.71%)

    Market Cap: $9.75B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TG Therapeutics Inc (TGTX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect TG Therapeutics (TGTX) to earn $1.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $999.31M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.25, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.

    RatingAnalystsShare
    Strong Buy112.5%
    Buy675.0%
    Hold00.0%
    Sell00.0%
    Strong Sell112.5%
    Consensus
    Buy
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 161.6% and revenue estimates rise 34.1%.

    Fiscal year ending Dec 31, 2026
    $1.12
    EPS consensus, revenue $999.31M
    Fiscal year ending Dec 31, 2027
    $2.93
    EPS consensus, revenue $1.34B
    Next report
    Jan 11, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.12$1.12 to $1.121$999.31M$980.00M to $1.01B7
    Dec 31, 2027$2.93$2.16 to $3.493$1.34B$1.22B to $1.42B8

    Quarterly Estimates

    The EPS consensus rises from $0.56 for the quarter ending Dec 31, 2026 to $0.60 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.56$0.32 to $0.7210$294.51M$261.56M to $315.00M10
    Mar 31, 2027$0.60$0.60 to $0.601$298.03M$283.00M to $314.40M3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 6 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202603
    Fiscal year ending Dec 31, 202722
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 12.0% from $1.00.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$1.12$0.95$0.95$0.95$1.00+12.4%
    Fiscal year ending Dec 31, 2027$2.93$2.71$2.71$2.97$3.13-6.4%
    Quarter ending Mar 31, 2027$0.60$0.45$0.45$0.45$0.45+33.3%

    Frequently Asked Questions About TGTX

    What is the TGTX stock forecast?

    Consensus analyst estimates put TG Therapeutics's EPS at $1.12 for the fiscal year ending Dec 31, 2026, on revenue of $999.31M. The consensus rating from 8 analysts is Buy.

    How do analysts rate TGTX stock?

    Of 8 analysts covering TG Therapeutics, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TGTX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.12, with estimates from $1.12 to $1.12 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.93, with estimates from $2.16 to $3.49 from 3 analysts.

    What revenue do analysts expect from TG Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $999.31M, with estimates from $980.00M to $1.01B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.34B, with estimates from $1.22B to $1.42B.

    How many analysts cover TGTX?

    8 analysts rate TG Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.